Pfizer to pay record penalty in improper marketing case
The Obama administration put drugmakers on notice that they will be forced to atone for improper marketing practices as prosecutors unveiled a record $2.3 billion settlement with Pfizer. Officials at the departments of Justice and Health and Human Services called the agreement a cautionary example of their strategy to team up with states to police errant healthcare businesses. The Pfizer unit Pharmacia & Upjohn pleaded guilty to a single felony charge that accused the company of marketing its anti-inflammatory drug Bextra for broader uses and higher dosages than those approved by the Food and Drug Administration.
- Senators Hear How Two-Midnight Rule Harms Patients, Hospitals
- 3 Management Lessons from a Supermarket Debacle
- Medicare Advantage Carriers See 'No Choice' But to Accept Cuts
- Physicians to Appeal 'Docs v. Glocks' Ruling in FL
- IOM Identifies GME Problems, Calls for Finance Changes
- Revenue Cycles Get a Boost from Simple JPEG Files
- Healthcare Costs Start With What We Eat
- CA Fines 8 Hospitals for Medical Errors
- Handshaking Spreads Germs. Get Over It.
- Anatomy of 3 Health System Rebranding Efforts